HWPC announced that the company participated in the bidding work for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Procurement Office, and the hydrochloride benidipine tablets are expected to win the bid. This drug is used for the treatment of primary hypertension and angina pectoris, with a specification of 8mg, packaging specification of 28 tablets/box, and an expected winning bid price of 7.19 yuan/box. The procurement cycle will be from the date of the selected results until December 31, 2028. The company's sales revenue is expected to be 166,300 yuan in 2024 and 5,097,600 yuan in the first half of 2025. If a procurement contract is signed and executed subsequently, it will help further expand sales scale, enhance market share and brand influence, and have a positive impact on the company's future operating performance
